Superiority of sandwich ELISA over competitive RIA for the estimation of ANP-270, an analogue of human atrial natriuretic factor.

ANP-270 is a 26 amino acid analogue of naturally occurring atrial natriuretic factor (ANF) which it was anticipated would be of value for the treatment of congestive heart failure and acute renal failure. Two sensitive assays--a radioimmunoassay (RIA) and a sandwich enzyme linked immunosorbent assay (ELISA)--were developed and validated for use in clinical investigations. The RIA utilized a single C terminal monoclonal antibody whereas two monoclonal antibodies directed against different epitopes were used for the ELISA. The two assays were comparable with respect to sensitivity and precision, but assay results obtained on samples from normal volunteers dosed intravenously with ANP-270 differed widely. Thus, in one volunteer the elimination half-life was estimated to be 123 min using RIA results but 6 min using the ELISA results. By reversed phase liquid chromatographic fractionation of plasma extracts followed by RIA and ELISA, these discrepancies were shown to be due to fragments of ANP-270 cross-reacting in the RIA but not in the ELISA. Consequently, the sandwich ELISA was the method of choice for estimating this compound in plasma.